Prostate adenoma or benign prostatic hypertrophy (BPH) is a benign disease of the prostate gland. It results in an increase in the volume of the prostate area located in contact with the urethra. Compression of the prostatic urethra by the adenoma can cause lower urinary tract disorders. The classic treatments in case of failure of medical treatment are endoscopic resection of the prostate and adenomectomy, but these techniques are characterized by a significant hemorrhagic risk that may require transfusions and prolonged hospitalization. Minimally invasive treatments with low morbidity have been developed to overcome these drawbacks. They allow to propose a therapeutic solution adapted to patients: not tolerating their medical treatment, wishing to keep antegrade ejaculation, elderly and/or frail, at risk of bleeding, wishing an ambulatory treatment, refusing the conventional surgical techniques. The Focal One® device was developed to treat prostate cancer using ultrasound energy. This energy is delivered through a probe placed in your rectum. Connected to this probe, an ultrasound machine will allow your doctor to see precisely which part of your prostate is being treated. By heating the prostate tissue to a very high temperature in one treatment session, the energy delivered will then destroy the tissue. Ultrasound guidance coupled with the localized nature of the treatment allows the targeted area to be treated while respecting the prostate tissue and structures adjacent to the prostate and thus reducing side effects. Treatment of prostate adenoma with HIFU would allow for localized destruction to reduce prostate volume. The reduction of the compression of the prostatic urethra thus obtained would allow an improvement of the urinary disorders. The treatment is performed transrectally under real-time ultrasound control, which allows the adjacent structures to be respected, thus preserving antegrade ejaculation and limiting the side effects.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
9
HIFU treatment of Benign Prostatic Hyperplasia
Hopital Edouard Herriot, service d'urologie
Lyon, France
The safety of HIFU treatment will be assessed by analyzing adverse events (serious and non-serious) reported during follow-up.
Time frame: 3 months
Evaluation of treatment performance by maximum urine output (Qmax)
Time frame: 1 and 3 months
Evaluation of treatment performance by residual post-void volume (RPM)
Time frame: 1 and 3 months
Evaluation of voiding symptomatology with IPSS questionnaire
Time frame: 1 and 3 months
Evaluation of quality of urinary life with Qol-IPSS score
Time frame: 1 and 3 months
Evaluation of quality of erection with IIEF-5 questionnaire
Time frame: 1 and 3 months
Evaluation of ejaculation quality with MSHQ-SF questionnaire
Time frame: 1 and 3 months
Evaluation of continence with ICIQ-SF questionnaire
Time frame: 1 and 3 months
Evaluation of the global impression of improvement scale with PGI-1 questionnaire
Time frame: 1 and 3 months
Evaluation of the change in the PSA rate
Time frame: 3 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.